BLAINJECTIONSOLUTIONPriority Review
Approved
Oct 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
SUSVIMO (ranibizumab) by Roche is vascular endothelial growth factor inhibitors [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2021.
Drug data last refreshed 11h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUSVIMO is a sustained-release, intraocular ranibizumab formulation approved in October 2021 for the treatment of retinal diseases driven by vascular endothelial growth factor (VEGF). It is a monoclonal antibody fragment that inhibits VEGF signaling to reduce pathological neovascularization and vascular permeability. This represents a novel delivery approach compared to the monthly intravitreal injection regimen of its predecessor, LUCENTIS.
Peak
SUSVIMO is in peak commercial lifecycle as a Roche-backed innovation in the competitive VEGF inhibitor space, likely supported by a focused specialty pharma sales and medical affairs team.
Mechanism of Action
Vascular Endothelial Growth Factor Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Started Nov 2025
250 enrolled
Neovascular Age-related Macular Degeneration
Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy
Started Sep 2025
266 enrolled
Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
Started Jun 2024
68 enrolled
Neovascular Age-related Macular DegenerationnAMD
A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
Started Dec 2023
0Neovascular Age-Related Macular Degeneration
A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss
Started Dec 2022
351 enrolled
Branch Retinal Vein Occlusion
Worked on SUSVIMO at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.